EUVIMEDSkopri EUVIMED
Multizentrische StudieKohortenstudieOpen access · CC BY 4.0

Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study

Susanna Hallberg iD, Björn Evertsson iD, Ellen Lillvall, Malin Boremalm iD, Pierre de Flon, Yunzhang Wang, Jonatan Salzer iD, Jan Lycke iD, Katharina Fink iD, Thomas Frisell iD, Faiez Al Nimer, Anders Svenningsson iD

European Journal of Neurology · 2024-08 · 31 (8)

DOI: 10.1111/ene.16331 ↗

At a glance

Multizentrische Studie in European Journal of Neurology, published online on 2024-05-25. Written by Susanna Hallberg and 11 co-authors. Institution: Department of Clinical Sciences, Karolinska Institutet, Danderyds Sjukhus, Stockholm, Sweden. Major MEDLINE topics: Agammaglobulinemia, Rituximab, Immunologic Factors, Multiple Sclerosis. Cited 15 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY 4.0). Funded by: Neuroförbundet, Stockholm läns landsting.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and purpose Mechanisms behind hypogammaglobulinaemia during rituximab treatment are poorly understood.

Methods

In this register‐based multi‐centre retrospective cohort study of multiple sclerosis (MS) patients in Sweden, 2745 patients from six participating Swedish MS centres were identified via the Swedish MS registry and included between 14 March 2008 and 25 January 2021. The exposure was treatment with at least one dose of rituximab for MS or clinically isolated syndrome, including data on treatment duration and doses. The degree of yearly decrease in immunoglobulin G (IgG) and immunoglobulin M (IgM) levels was evaluated.

Results

The mean decrease in IgG was 0.27 (95% confidence interval 0.17–0.36) g/L per year on rituximab treatment, slightly less in older patients, and without significant difference between sexes. IgG or IgM below the lower limit of normal (

Subjects

MeSH terms (MEDLINE)

AgammaglobulinemiaRituximabImmunologic FactorsMultiple SclerosisHumansSwedenFemaleMaleAdultMiddle AgedRetrospective StudiesRegistriesCohort StudiesImmunoglobulin G

Author keywords

IgG decreaseIgM decreasedisease‐modifying therapyhypogammaglobulinaemiaimmunoglobulin decreasemultiple sclerosisreal‐world datarituximab therapy

Substances

RituximabImmunologic FactorsImmunoglobulin G

Authors and institutions

  • Department of Clinical Sciences, Karolinska Institutet, Danderyds Sjukhus, Stockholm, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
  • Department of Clinical Sciences, Neurosciences, Unit of Neurology, Östersund, Umeå University, Umeå, Sweden.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

ORCID profiles: Susanna Hallberg, Björn Evertsson, Malin Boremalm, Jonatan Salzer, Jan Lycke, Katharina Fink, Thomas Frisell, Anders Svenningsson

Funding

  • Neuroförbundet
  • Stockholm läns landsting

Cite

APA

Hallberg, S., Evertsson, B., Lillvall, E., Boremalm, M., de Flon, P., Wang, Y., Salzer, J., Lycke, J., Fink, K., Frisell, T., Al Nimer, F., & Svenningsson, A. (2024). Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European Journal of Neurology, 31(8). https://doi.org/10.1111/ene.16331

Vancouver

Hallberg S, Evertsson B, Lillvall E, Boremalm M, de Flon P, Wang Y, et al. Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European Journal of Neurology. 2024;31(8). doi:10.1111/ene.16331

BibTeX
@article{Hallberg2024,
  author = {Hallberg, Susanna and Evertsson, Björn and Lillvall, Ellen and Boremalm, Malin and de Flon, Pierre and Wang, Yunzhang and Salzer, Jonatan and Lycke, Jan and Fink, Katharina and Frisell, Thomas and Al Nimer, Faiez and Svenningsson, Anders},
  title = {Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {8},
  doi = {10.1111/ene.16331}
}
Start for free →